PEG-MGF
Aliases: PEGylated Mechano Growth Factor
Last verified: 2026-09-23
The short version
PEGylated version of MGF with extended half-life (days instead of minutes) for systemic muscle-recovery effects. Key fact: Human data are limited: small trials or case-series reports exist, without large randomized studies. Preclinical only. Status: research chemical. Not approved; WADA-banned.
Identity & type
- Molecular type
- fragment
- Origin
- PEGylated version of MGF with extended half-life (days instead of minutes) for systemic muscle-recovery effects.
Mechanism of action
Same as MGF (satellite-cell activation), with PEGylation protecting the peptide from proteolysis.
not confirmed in humans
Dosing & routes
Official / clinical context
No approved official document exists for PEG-MGF. Any protocols mentioned are to be read as information, not as a recommendation.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
200–400 mcg SC 2–3× weekly. The PEGylated longer-acting version — used systemically 1–2× weekly; effects modest, more often an add-on than standalone.
Unverified self-reports. Not medical advice. Not endorsement.
Expected effects (community)
The PEGylated longer-acting version — used systemically 1–2× weekly; effects modest, more often an add-on than standalone.
Protocol — official vs community
Official / label
No approved protocol exists — investigational agent. The PEGylated form exists only to extend MGF's minute-scale half-life; it remains preclinical.
Duration: —
WADA-prohibited (S2). PEGylation changes pharmacokinetics, not the regulatory or evidentiary status.
Community (anecdotal)
200–400 mcg SC 2–3× weekly, systemic rather than site-specific. Approximate and unvalidated.
- Cycle:
- 4–6 weeks.
- Break:
- 4 weeks off between cycles.
Community preference for PEG-MGF over MGF rests on the longer half-life claim, which is real biochemistry applied to an otherwise unvalidated protocol. Rare hypoglycemia is reported anecdotally.
Human evidence
Human data are limited: small trials or case-series reports exist, without large randomized studies. Preclinical only.
Preclinical evidence
Preclinical only.
Known risks
- Local reactions, rare hypoglycemia; safety unknown.characterized
- Unregulated injectable supply — sterility, purity and accurate dose not assuredtheoretical
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- Long-term human safety
- Optimal dose and pharmacokinetics
Frequently asked questions
References
Systematic references are being expanded; verify sources directly before any decision.